Publications
2023
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..
2023.
Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..
2023.
Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Ghram M, Morris G, Culjkovic-Kraljacic B, Mars J-C, Gendron P, Skrabanek L, Revuelta MVictoria, Cerchietti L, Guzman ML, Borden KLB.
2023.
The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.. EMBO J. 42(7):e110496.
Ghram M, Morris G, Culjkovic-Kraljacic B, Mars J-C, Gendron P, Skrabanek L, Revuelta MVictoria, Cerchietti L, Guzman ML, Borden KLB.
2023.
The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.. EMBO J. 42(7):e110496.
Ghram M, Morris G, Culjkovic-Kraljacic B, Mars J-C, Gendron P, Skrabanek L, Revuelta MVictoria, Cerchietti L, Guzman ML, Borden KLB.
2023.
The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.. EMBO J. 42(7):e110496.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..
2023.
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..
2023.
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..
2023.
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..
2023.
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.